02:19 PM EST, 11/18/2025 (MT Newswires) -- Tivic Health Systems ( TIVC ) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.

The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.

The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.

Entolimod has received Fast Track and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.

Price: 1.83, Change: +0.32, Percent Change: +21.56